Florence Borot

1 month ago | nature.com | Florence Borot |Olivier Humbert |Emily Fields |Stefan Radtke |Mark R. Enstrom |Abdullah Ali | +7 more

AbstractThe selection of genetically engineered immune or hematopoietic cells in vivo after gene editing remains a clinical problem and requires a method to spare on-target toxicity to normal cells. Here, we develop a base editing approach exploiting a naturally occurring CD33 single nucleotide polymorphism leading to removal of full-length CD33 surface expression on edited cells.